The Experts below are selected from a list of 105 Experts worldwide ranked by ideXlab platform

John L Sever - One of the best experts on this subject based on the ideXlab platform.

  • safety of anthrax vaccine a review by the anthrax vaccine expert committee avec of adverse events reported to the vaccine adverse event reporting system vaers
    Pharmacoepidemiology and Drug Safety, 2002
    Co-Authors: Alan I Brenner, Arnold D Gale, Lawrence H Moulton, Jeremy M. Lyle, John L Sever, David J. West
    Abstract:

    SUMMARY Purpose To assess the safety of a licensed anthrax vaccine given to nearly 400 000 US military personnel, reports of adverse events (AEs) submitted to the Vaccine Adverse Event Reporting System (VAERS) were reviewed and evaluated medically. Methods The Anthrax Vaccine Expert Committee (AVEC), a civilian panel of private-sector physicians and other scientists, reviewed 602 VAERS reports using a Delphic approach (structured expert consensus) to assess the causal relationship between vaccination and the reported AEs and sought to identify unexpected patterns in the occurrence of medically important events. Reports were entered into a database and used to profile AEs with respect to person, type/location, relative frequency, severity/impact, concomitant illness or receipt of other drugs or vaccines, and vaccine lot. Results Nearly half the reports noted a local injection-site AE, with more than one-third of these involving a moderate to large degree of inflammation. Six events qualified as serious AEs (SAEs), and all were judged to be certain consequences of vaccination. Three-quarters of the reports cited a systemic AE (most common: flu-like symptoms, malaise, rash, arthralgia, headache), but only six individual medically important events were judged possibly or probably due to vaccine (aggravation of spondyloarthropathy (2), anaphylactoid reaction, arthritis (2), bronchiolitis obliterans organizing pneumonia). Conclusions Since some cases of local inflammation involved Distal Paresthesia, AVEC recommends giving subcutaneous injections of AVA over the inferior deltoid instead of the triceps to avoid compression injury to the ulnar nerve. At this time, ongoing evaluation of VAERS reports does not suggest a high frequency or unusual pattern of serious or other medically important AEs. Copyright # 2002 John Wiley & Sons, Ltd.

Erick Gamelin - One of the best experts on this subject based on the ideXlab platform.

  • prevention of oxaliplatin related neurotoxicity by calcium and magnesium infusions a retrospective study of 161 patients receiving oxaliplatin combined with 5 fluorouracil and leucovorin for advanced colorectal cancer
    Clinical Cancer Research, 2004
    Co-Authors: Laurence Gamelin, Michele Boisdroncelle, R Delva, Veronique Guerinmeyer, Norbert Ifrah, Alain Morel, Erick Gamelin
    Abstract:

    Purpose: Oxaliplatin is active in colorectal cancer. Sensory neurotoxicity is its dose-limiting toxicity. It may come from an effect on neuronal voltage-gated Na channels, via the liberation one its metabolite, oxalate. We decided to use Ca and Mg as oxalate chelators. Experimental Design: A retrospective cohort of 161 patients treated with oxaliplatin 5-fluorouracil and leucovorin for advanced colorectal cancer, with three regimens of oxaliplatin (85 mg/m 2 /2w, 100/2w, 130/3w) was identified. Ninety-six patients received infusions of Ca gluconate and Mg sulfate (1 g) before and after oxaliplatin (Ca/Mg group) and 65 did not. Results: Only 4% of patients withdrew for neurotoxicity in the Ca/Mg group versus 31% in the control group (P 0.000003). The tumor response rate was similar in both groups. The percentage of patients with grade 3 Distal Paresthesia was lower in Ca/Mg group (7 versus 26%, P 0.001). Acute symptoms such as Distal and lingual Paresthesia were much less frequent and severe (P 10 -7 ), and pseudolaryngospasm was never reported in Ca/Mg group. At the end of the treatment, 20% of patients in Ca/Mg group had neuropathy versus 45% (P 0.003). Patients with grade 2 and 3 at the end of the treatment in the 85 mg/m 2 oxali

  • Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004
    Co-Authors: Laurence Gamelin, R Delva, Norbert Ifrah, Alain Morel, Michele Boisdron-celle, Véronique Guérin-meyer, Erick Gamelin
    Abstract:

    Oxaliplatin is active in colorectal cancer. Sensory neurotoxicity is its dose-limiting toxicity. It may come from an effect on neuronal voltage-gated Na channels, via the liberation one its metabolite, oxalate. We decided to use Ca and Mg as oxalate chelators. A retrospective cohort of 161 patients treated with oxaliplatin + 5-fluorouracil and leucovorin for advanced colorectal cancer, with three regimens of oxaliplatin (85 mg/m(2)/2w, 100/2w, 130/3w) was identified. Ninety-six patients received infusions of Ca gluconate and Mg sulfate (1 g) before and after oxaliplatin (Ca/Mg group) and 65 did not. Only 4% of patients withdrew for neurotoxicity in the Ca/Mg group versus 31% in the control group (P = 0.000003). The tumor response rate was similar in both groups. The percentage of patients with grade 3 Distal Paresthesia was lower in Ca/Mg group (7 versus 26%, P = 0.001). Acute symptoms such as Distal and lingual Paresthesia were much less frequent and severe (P = 10(-7)), and pseudolaryngospasm was never reported in Ca/Mg group. At the end of the treatment, 20% of patients in Ca/Mg group had neuropathy versus 45% (P = 0.003). Patients with grade 2 and 3 at the end of the treatment in the 85 mg/m(2) oxaliplatin group recovered significantly more rapidly from neuropathy than patients without Ca/Mg. Ca/Mg infusions seem to reduce incidence and intensity of acute oxaliplatin-induced symptoms and might delay cumulative neuropathy, especially in 85 mg/m(2) oxaliplatin dosage.

David J. West - One of the best experts on this subject based on the ideXlab platform.

  • safety of anthrax vaccine a review by the anthrax vaccine expert committee avec of adverse events reported to the vaccine adverse event reporting system vaers
    Pharmacoepidemiology and Drug Safety, 2002
    Co-Authors: Alan I Brenner, Arnold D Gale, Lawrence H Moulton, Jeremy M. Lyle, John L Sever, David J. West
    Abstract:

    SUMMARY Purpose To assess the safety of a licensed anthrax vaccine given to nearly 400 000 US military personnel, reports of adverse events (AEs) submitted to the Vaccine Adverse Event Reporting System (VAERS) were reviewed and evaluated medically. Methods The Anthrax Vaccine Expert Committee (AVEC), a civilian panel of private-sector physicians and other scientists, reviewed 602 VAERS reports using a Delphic approach (structured expert consensus) to assess the causal relationship between vaccination and the reported AEs and sought to identify unexpected patterns in the occurrence of medically important events. Reports were entered into a database and used to profile AEs with respect to person, type/location, relative frequency, severity/impact, concomitant illness or receipt of other drugs or vaccines, and vaccine lot. Results Nearly half the reports noted a local injection-site AE, with more than one-third of these involving a moderate to large degree of inflammation. Six events qualified as serious AEs (SAEs), and all were judged to be certain consequences of vaccination. Three-quarters of the reports cited a systemic AE (most common: flu-like symptoms, malaise, rash, arthralgia, headache), but only six individual medically important events were judged possibly or probably due to vaccine (aggravation of spondyloarthropathy (2), anaphylactoid reaction, arthritis (2), bronchiolitis obliterans organizing pneumonia). Conclusions Since some cases of local inflammation involved Distal Paresthesia, AVEC recommends giving subcutaneous injections of AVA over the inferior deltoid instead of the triceps to avoid compression injury to the ulnar nerve. At this time, ongoing evaluation of VAERS reports does not suggest a high frequency or unusual pattern of serious or other medically important AEs. Copyright # 2002 John Wiley & Sons, Ltd.

Laurence Gamelin - One of the best experts on this subject based on the ideXlab platform.

  • prevention of oxaliplatin related neurotoxicity by calcium and magnesium infusions a retrospective study of 161 patients receiving oxaliplatin combined with 5 fluorouracil and leucovorin for advanced colorectal cancer
    Clinical Cancer Research, 2004
    Co-Authors: Laurence Gamelin, Michele Boisdroncelle, R Delva, Veronique Guerinmeyer, Norbert Ifrah, Alain Morel, Erick Gamelin
    Abstract:

    Purpose: Oxaliplatin is active in colorectal cancer. Sensory neurotoxicity is its dose-limiting toxicity. It may come from an effect on neuronal voltage-gated Na channels, via the liberation one its metabolite, oxalate. We decided to use Ca and Mg as oxalate chelators. Experimental Design: A retrospective cohort of 161 patients treated with oxaliplatin 5-fluorouracil and leucovorin for advanced colorectal cancer, with three regimens of oxaliplatin (85 mg/m 2 /2w, 100/2w, 130/3w) was identified. Ninety-six patients received infusions of Ca gluconate and Mg sulfate (1 g) before and after oxaliplatin (Ca/Mg group) and 65 did not. Results: Only 4% of patients withdrew for neurotoxicity in the Ca/Mg group versus 31% in the control group (P 0.000003). The tumor response rate was similar in both groups. The percentage of patients with grade 3 Distal Paresthesia was lower in Ca/Mg group (7 versus 26%, P 0.001). Acute symptoms such as Distal and lingual Paresthesia were much less frequent and severe (P 10 -7 ), and pseudolaryngospasm was never reported in Ca/Mg group. At the end of the treatment, 20% of patients in Ca/Mg group had neuropathy versus 45% (P 0.003). Patients with grade 2 and 3 at the end of the treatment in the 85 mg/m 2 oxali

  • Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004
    Co-Authors: Laurence Gamelin, R Delva, Norbert Ifrah, Alain Morel, Michele Boisdron-celle, Véronique Guérin-meyer, Erick Gamelin
    Abstract:

    Oxaliplatin is active in colorectal cancer. Sensory neurotoxicity is its dose-limiting toxicity. It may come from an effect on neuronal voltage-gated Na channels, via the liberation one its metabolite, oxalate. We decided to use Ca and Mg as oxalate chelators. A retrospective cohort of 161 patients treated with oxaliplatin + 5-fluorouracil and leucovorin for advanced colorectal cancer, with three regimens of oxaliplatin (85 mg/m(2)/2w, 100/2w, 130/3w) was identified. Ninety-six patients received infusions of Ca gluconate and Mg sulfate (1 g) before and after oxaliplatin (Ca/Mg group) and 65 did not. Only 4% of patients withdrew for neurotoxicity in the Ca/Mg group versus 31% in the control group (P = 0.000003). The tumor response rate was similar in both groups. The percentage of patients with grade 3 Distal Paresthesia was lower in Ca/Mg group (7 versus 26%, P = 0.001). Acute symptoms such as Distal and lingual Paresthesia were much less frequent and severe (P = 10(-7)), and pseudolaryngospasm was never reported in Ca/Mg group. At the end of the treatment, 20% of patients in Ca/Mg group had neuropathy versus 45% (P = 0.003). Patients with grade 2 and 3 at the end of the treatment in the 85 mg/m(2) oxaliplatin group recovered significantly more rapidly from neuropathy than patients without Ca/Mg. Ca/Mg infusions seem to reduce incidence and intensity of acute oxaliplatin-induced symptoms and might delay cumulative neuropathy, especially in 85 mg/m(2) oxaliplatin dosage.

R Delva - One of the best experts on this subject based on the ideXlab platform.

  • prevention of oxaliplatin related neurotoxicity by calcium and magnesium infusions a retrospective study of 161 patients receiving oxaliplatin combined with 5 fluorouracil and leucovorin for advanced colorectal cancer
    Clinical Cancer Research, 2004
    Co-Authors: Laurence Gamelin, Michele Boisdroncelle, R Delva, Veronique Guerinmeyer, Norbert Ifrah, Alain Morel, Erick Gamelin
    Abstract:

    Purpose: Oxaliplatin is active in colorectal cancer. Sensory neurotoxicity is its dose-limiting toxicity. It may come from an effect on neuronal voltage-gated Na channels, via the liberation one its metabolite, oxalate. We decided to use Ca and Mg as oxalate chelators. Experimental Design: A retrospective cohort of 161 patients treated with oxaliplatin 5-fluorouracil and leucovorin for advanced colorectal cancer, with three regimens of oxaliplatin (85 mg/m 2 /2w, 100/2w, 130/3w) was identified. Ninety-six patients received infusions of Ca gluconate and Mg sulfate (1 g) before and after oxaliplatin (Ca/Mg group) and 65 did not. Results: Only 4% of patients withdrew for neurotoxicity in the Ca/Mg group versus 31% in the control group (P 0.000003). The tumor response rate was similar in both groups. The percentage of patients with grade 3 Distal Paresthesia was lower in Ca/Mg group (7 versus 26%, P 0.001). Acute symptoms such as Distal and lingual Paresthesia were much less frequent and severe (P 10 -7 ), and pseudolaryngospasm was never reported in Ca/Mg group. At the end of the treatment, 20% of patients in Ca/Mg group had neuropathy versus 45% (P 0.003). Patients with grade 2 and 3 at the end of the treatment in the 85 mg/m 2 oxali

  • Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004
    Co-Authors: Laurence Gamelin, R Delva, Norbert Ifrah, Alain Morel, Michele Boisdron-celle, Véronique Guérin-meyer, Erick Gamelin
    Abstract:

    Oxaliplatin is active in colorectal cancer. Sensory neurotoxicity is its dose-limiting toxicity. It may come from an effect on neuronal voltage-gated Na channels, via the liberation one its metabolite, oxalate. We decided to use Ca and Mg as oxalate chelators. A retrospective cohort of 161 patients treated with oxaliplatin + 5-fluorouracil and leucovorin for advanced colorectal cancer, with three regimens of oxaliplatin (85 mg/m(2)/2w, 100/2w, 130/3w) was identified. Ninety-six patients received infusions of Ca gluconate and Mg sulfate (1 g) before and after oxaliplatin (Ca/Mg group) and 65 did not. Only 4% of patients withdrew for neurotoxicity in the Ca/Mg group versus 31% in the control group (P = 0.000003). The tumor response rate was similar in both groups. The percentage of patients with grade 3 Distal Paresthesia was lower in Ca/Mg group (7 versus 26%, P = 0.001). Acute symptoms such as Distal and lingual Paresthesia were much less frequent and severe (P = 10(-7)), and pseudolaryngospasm was never reported in Ca/Mg group. At the end of the treatment, 20% of patients in Ca/Mg group had neuropathy versus 45% (P = 0.003). Patients with grade 2 and 3 at the end of the treatment in the 85 mg/m(2) oxaliplatin group recovered significantly more rapidly from neuropathy than patients without Ca/Mg. Ca/Mg infusions seem to reduce incidence and intensity of acute oxaliplatin-induced symptoms and might delay cumulative neuropathy, especially in 85 mg/m(2) oxaliplatin dosage.